In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Long-term follow-up after reconstructive surgery of hypertrophic cardiomyopathy with multi-level obstruction.

Session Poster Session 2

Speaker Yulia Frolova

Event : Heart Failure 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Hypertrophic Cardiomyopathy
  • Session type : Poster Session

Authors : YF Frolova (Moscow,RU)

YF Frolova1 , 1Petrovsky National Russian Research Center of Surgery, Cardio Surgery of Heart Failure - Moscow - Russian Federation ,


Aim : To study morphofunctional changes of the heart, genetic testing, the indications and long-term results of surgical treatment of patients with hypertrophic cardiomyopathy (HCM) with multilevel obstruction.

Material and methods : From 2009 to 2017 a total of 124 patients (pts) with HCM (63 women, 61 men) were analyzed. The mean age was 53±2,8 years. 79 (64%) pts had III – IV FC NYHA (functional class, New York Heart Association). According to ECHO, there was found a significant increase of the thickness of interventricular septum (IVS) (2,24±0,03 sm,p<0.05), increase of the gradient at left ventricle (LV)  outflow tract (OP) (71,5±6.9 mm hg,p<0.05) and unreliable decrease in end-systolic volume (ESVLV) (31,3± 2.6 ml). According to MRI/MCT of the heart in 77pts there was registered increased volume of the anterior and posterior papillary muscles, to their dystopia with reduction of ESVLV and significantly increased myocardial mass of LV in diastole (311±45gr;p<0.05), which we determined as a diffuse-generalized form of HCM; in 22 pts – asymmetric form of HCM. 63 pts with the obstructive form of HCM underwent operation of the extended myectomy with parietal resection of the papillary muscles in conditions of open heart surgery (included 42 pts with replacement of the mitral valve), 5 – endovascular ablation of septal perforator, 27 - implantation of cardioverter defibrillator (ICD), 39 – conservative therapy.

Results : In pts after open heart surgery found a significant improvement in a 1, 3, 5 and 7 years after surgery: I FC (NYHA) – 34 (57%) patients, of FC II (NYHA) – in 25 (53%) patients. Triggering ICD was observed in 5 (19%) pts in the postoperative period. 4 patients (6,3%) died due to life-threatening arrhythmias.  ECHO revealed a significant decrease in thickness  of IVS (from 2.27±0.02 to 1.5±0.02 cm, p<0.05) and the gradient at OPLV (71,38±6.7 to 4,75±1.3 mm hg, p<0.05), the false increase of ESVLV (28,31±2.8 ml to 34.4±2,9ml p>0.05). Classic "sarcomeric" genetic mutations were surprisingly only found in 14% pts, in86% pts were found other genetic disorders.

Conclusion : Reconstructive extended myectomy with the parietal resection of papillary muscle and mitral valve replacement with chordal preservation provides several long-term benefits in pts with HCM. Many questions remain unanswered about the phenotype-genotype correlations and the prognostic value of particular mutations in different genes.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are